Literature DB >> 12094252

Non-DNA-binding Ikaros isoform gene expressed in adult B-precursor acute lymphoblastic leukemia.

K Nishii1, N Katayama, H Miwa, M Shikami, E Usui, M Masuya, H Araki, F Lorenzo, T Ogawa, T Kyo, K Nasu, H Shiku, K Kita.   

Abstract

Ikaros, a zinc finger transcription factor, is essential for lymphoid development. Mutant mice expressing dominant-negative Ikaros gene (Ikaros) isoforms develop an aggressive form of lymphoid malignancies. We examined the expression of Ikaros isoforms in 11 leukemic cell lines and adult acute lymphoblastic leukemia cells from 36 patients with B-precursor acute lymphoblastic leukemia (pre-B ALL) and nine with T-precursor acute lymphoblastic leukemia (pre-T ALL), using reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. In one pre-B ALL cell line, INC cells, and primary leukemic cells from 16 patients with pre-B ALL, we found the predominant expression of a non-DNA-binding Ikaros isoform, Ik-6. However, Ik-6 was not detected in pre-T ALL cells. All of pre-B ALL cells expressing Ik-6 were CD10(+), whereas CD10(-) pre-B ALL cells did not express Ik-6. The expression of Ik-6 was not related to karyotype abnormalities such as t(9;22) and t(4;11). Proteins from the cells that expressed Ik-6 alone failed to bind to the Ikaros protein-specific binding sequence in DNA. Ikaros proteins lacking the DNA binding sequences were detected in the cytoplasm but not in the nucleus of the cells. When INC and primary pre-B ALL cells that express Ik-6 alone were irradiated and cultured in the absence of serum, these cells produced functional Ikaros isoforms, Ik-1 and Ik-2. Purified CD19(+) CD10(-) and CD19(+) CD10(+) cells from normal human bone marrow did not express Ik-6. The predominant expression of Ik-6, which is the result of post-transcription dysregulation, is characteristic of adult pre-B ALL, especially CD10(+) pre-B ALL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12094252     DOI: 10.1038/sj.leu.2402533

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Expression of a non-DNA-binding isoform of Helios induces T-cell lymphoma in mice.

Authors:  Zheng Zhang; C Scott Swindle; John T Bates; Rose Ko; Claudiu V Cotta; Christopher A Klug
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

2.  Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

Authors:  J M Boer; A van der Veer; D Rizopoulos; M Fiocco; E Sonneveld; H A de Groot-Kruseman; R P Kuiper; P Hoogerbrugge; M Horstmann; M Zaliova; C Palmi; J Trka; E Fronkova; M Emerenciano; M do Socorro Pombo-de-Oliveira; W Mlynarski; T Szczepanski; K Nebral; A Attarbaschi; N Venn; R Sutton; C J Schwab; A Enshaei; A Vora; M Stanulla; M Schrappe; G Cazzaniga; V Conter; M Zimmermann; A V Moorman; R Pieters; M L den Boer
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

3.  TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia.

Authors:  Hatem E Sabaawy; Mizuki Azuma; Lisa J Embree; Huai-Jen Tsai; Matthew F Starost; Dennis D Hickstein
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

4.  Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice.

Authors:  Alexis Dumortier; Robin Jeannet; Peggy Kirstetter; Eva Kleinmann; MacLean Sellars; Nuno R dos Santos; Christelle Thibault; Jochen Barths; Jacques Ghysdael; Jennifer A Punt; Philippe Kastner; Susan Chan
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

5.  Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.

Authors:  Michelle L Churchman; Jonathan Low; Chunxu Qu; Elisabeth M Paietta; Lawryn H Kasper; Yunchao Chang; Debbie Payne-Turner; Mark J Althoff; Guangchun Song; Shann-Ching Chen; Jing Ma; Michael Rusch; Dan McGoldrick; Michael Edmonson; Pankaj Gupta; Yong-Dong Wang; William Caufield; Burgess Freeman; Lie Li; John C Panetta; Sharyn Baker; Yung-Li Yang; Kathryn G Roberts; Kelly McCastlain; Ilaria Iacobucci; Jennifer L Peters; Victoria E Centonze; Faiyaz Notta; Stephanie M Dobson; Sasan Zandi; John E Dick; Laura Janke; Junmin Peng; Kiran Kodali; Vishwajeeth Pagala; Jaeki Min; Anand Mayasundari; Richard T Williams; Cheryl L Willman; Jacob Rowe; Selina Luger; Ross A Dickins; R Kiplin Guy; Taosheng Chen; Charles G Mullighan
Journal:  Cancer Cell       Date:  2015-08-27       Impact factor: 31.743

6.  Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia.

Authors:  Philippe Kastner; Arnaud Dupuis; Marie-Pierre Gaub; Raoul Herbrecht; Patrick Lutz; Susan Chan
Journal:  Am J Blood Res       Date:  2013-01-17

7.  Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.

Authors:  Michelle L Churchman; Kathryn Evans; Jennifer Richmond; Alissa Robbins; Luke Jones; Irina M Shapiro; Jonathan A Pachter; David T Weaver; Peter J Houghton; Malcolm A Smith; Richard B Lock; Charles G Mullighan
Journal:  JCI Insight       Date:  2016-04-07

Review 8.  MicroRNAs in B cell development and malignancy.

Authors:  Thilini R Fernando; Norma I Rodriguez-Malave; Dinesh S Rao
Journal:  J Hematol Oncol       Date:  2012-03-08       Impact factor: 17.388

9.  Signaling proteins and transcription factors in normal and malignant early B cell development.

Authors:  Patricia Pérez-Vera; Adriana Reyes-León; Ezequiel M Fuentes-Pananá
Journal:  Bone Marrow Res       Date:  2011-05-20

10.  A novel, non-canonical splice variant of the Ikaros gene is aberrantly expressed in B-cell lymphoproliferative disorders.

Authors:  Daria Capece; Francesca Zazzeroni; Maria Michela Mancarelli; Daniela Verzella; Mariafausta Fischietti; Ambra Di Tommaso; Rita Maccarone; Sara Plebani; Mauro Di Ianni; Alberto Gulino; Edoardo Alesse
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.